TVTX - שולי רווח נקי ממכירות Travere Therapeutics, Inc.

Travere Therapeutics Inc - לוגו גרפי של המנפיק TVTX

Travere Therapeutics (TVTX) bases its strategy on developing a portfolio of therapies for rare kidney pathologies. Current net profit margins demonstrate progress toward this goal, with the -23.70 mark reflecting the latest data. Growth is hindered by dependence on regulators and patent rights, although the uniqueness of the drugs helps the company maintain a monopoly status within its niche.

TVTX: שולי רווח נקי Travere Corp 04.07.2022 - 20.11.2026

Retrophin (TVTX) - פילוחי מדדים ודוחות פיננסיים

- שווי שוק ותחזית יעד של אנליסטים:
ניתוח מקיף של החברה:Travere Therapeutics, Inc., TVTX
מוצר המיוצר על ידי Travere Therapeutics Inc

Sales margin measures the share of net profit in total revenue, reflecting the final efficiency of cost management after deducting all operating and tax expenses. By analyzing the net margin percentage, an investor assesses the ability of Travere Therapeutics (TVTX) to convert exclusive rights to the drug Filspari into actual cash flow, given the specific costs associated with bringing orphan drugs to market.